Lilly
3Q Revenues: $5.2 billion (+14%)
3Q Loss: $465.6 million (earnings were $926.3 million in 3Q07)
YTD Revenues: $15.2 billion (+13%)
YTD Earnings: $1.6 billion (-26%)
Comments: Zyprexa sales were $1.2 billion in the quarter (+2%). Cymbalta sales were $716.4 million (+40%). Gemzar sales were $440.2 million (+12%). Humalog sales were up 19% to $432.6 million. Cialis sales were $376.6 million (+21%). Alimta sales were $313.9 million (46%). Strattera sales were $149.5 million (+15%). Byetta sales were $201.2 million (+22%). R&D expenses were $953.0 million in the quarter (+13%). The 3Q08 loss was due to charges totaling $1.5 billion related to pending and resolved Zyprexa investigations. In the quarter, the company completed the $64.0 million acquisition of SGX Pharmaceuticals, a San Diego-based biotechnology company.
Magazine
